Systematic assessment of clinical outcomes and toxicities of proton radiotherapy for reirradiation - PubMed (original) (raw)
Review
Systematic assessment of clinical outcomes and toxicities of proton radiotherapy for reirradiation
Vivek Verma et al. Radiother Oncol. 2017 Oct.
Abstract
Reirradiation (reRT) for locoregional recurrences poses unique challenges and risks; re-treatment using proton beam radiotherapy (PBT) could prove advantageous. Assessing clinical outcomes and toxicity profiles, this systematic review comprehensively evaluated available evidence regarding PBT reRT. Fourteen original investigations across central nervous system (CNS) (n=6), head/neck (H&N) (n=4), lung (n=2), and gastrointestinal (n=2) malignancies were analyzed. PBT for recurrent uveal melanoma achieved 5-year eye retention of 55%; for chordomas, reRT afforded a 2-year local control and overall survival (OS) of 85% and 80%, respectively. Multiple PBT reRT studies for adult gliomas illustrate no grade ≥3 toxicities. Two pediatric CNS tumor studies demonstrated the safety and efficacy of reRT, with one total grade 3 toxicity and achievement of longer-term OS. PBT for H&N malignancies shows appropriate local/locoregional control and favorable toxicity profiles versus historical photon-based methods, including low (9-10%) rates of feeding tube placement. PBT for recurrent lung cancer can achieve favorable survival with expected toxicities/complications of reRT, especially with concurrent chemotherapy and centrally located recurrences. Lastly, PBT reRT in gastrointestinal malignancies induced very few high-grade complications. Hence, based on the limited existing data, PBT is a notably safe reRT modality for effective salvage of recurrent disease. Institutional experiences must continue to be reported: dosimetric correlations, late toxicities, and advanced PBT techniques.
Keywords: Adverse effects; Proton radiation therapy; Reirradiation; Salvage therapy; Tissue complications; Toxicity.
Copyright © 2017 Elsevier B.V. All rights reserved.
Similar articles
- Proton reirradiation for recurrent or new primary breast cancer in the setting of prior breast irradiation.
Choi JI, Khan AJ, Powell SN, McCormick B, Lozano AJ, Del Rosario G, Mamary J, Liu H, Fox P, Gillespie E, Braunstein LZ, Mah D, Cahlon O. Choi JI, et al. Radiother Oncol. 2021 Dec;165:142-151. doi: 10.1016/j.radonc.2021.10.010. Epub 2021 Oct 22. Radiother Oncol. 2021. PMID: 34688807 Free PMC article. - Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer.
Yegya-Raman N, Berman AT, Ciunci CA, Friedes C, Berlin E, Iocolano M, Wang X, Lai C, Levin WP, Cengel KA, O'Reilly SE, Cohen RB, Aggarwal C, Marmarelis ME, Singh AP, Sun L, Bradley JD, Plastaras JP, Simone CB 2nd, Langer CJ, Feigenberg SJ. Yegya-Raman N, et al. Int J Radiat Oncol Biol Phys. 2024 May 1;119(1):56-65. doi: 10.1016/j.ijrobp.2023.08.047. Epub 2023 Aug 29. Int J Radiat Oncol Biol Phys. 2024. PMID: 37652303 Clinical Trial. - Proton beam therapy reirradiation for breast cancer: Multi-institutional prospective PCG registry analysis.
Thorpe CS, Niska JR, Girardo ME, Kosiorek HE, McGee LA, Hartsell WF, Larson GL, Tsai HK, Rossi CJ, Rosen LR, Vargas CE. Thorpe CS, et al. Breast J. 2019 Nov;25(6):1160-1170. doi: 10.1111/tbj.13423. Epub 2019 Jul 23. Breast J. 2019. PMID: 31338974 - Proton Therapy in Non-small Cell Lung Cancer.
Mesko S, Gomez D. Mesko S, et al. Curr Treat Options Oncol. 2018 Nov 27;19(12):76. doi: 10.1007/s11864-018-0588-z. Curr Treat Options Oncol. 2018. PMID: 30483900 Review. - Proton Reirradiation: Expert Recommendations for Reducing Toxicities and Offering New Chances of Cure in Patients With Challenging Recurrence Malignancies.
Simone CB 2nd, Plastaras JP, Jabbour SK, Lee A, Lee NY, Choi JI, Frank SJ, Chang JY, Bradley J. Simone CB 2nd, et al. Semin Radiat Oncol. 2020 Jul;30(3):253-261. doi: 10.1016/j.semradonc.2020.02.007. Semin Radiat Oncol. 2020. PMID: 32503791 Free PMC article. Review.
Cited by
- Proton Therapy in Uveal Melanoma.
Chan AW, Lin H, Yacoub I, Chhabra AM, Choi JI, Simone CB 2nd. Chan AW, et al. Cancers (Basel). 2024 Oct 16;16(20):3497. doi: 10.3390/cancers16203497. Cancers (Basel). 2024. PMID: 39456591 Free PMC article. Review. - Comparative Evaluation of Proton Therapy and Volumetric Modulated Arc Therapy for Brachial Plexus Sparing in the Comprehensive Reirradiation of High-Risk Recurrent Breast Cancer.
Choi JI, McCormick B, Park P, Millar M, Walker K, Tung CC, Huang S, Florio P, Chen CC, Lozano A, Hanlon AL, Fox J, Xu AJ, Zinovoy M, Mueller B, Bakst R, LaPlant Q, Braunstein LZ, Khan AJ, Powell SN, Cahlon O. Choi JI, et al. Adv Radiat Oncol. 2023 Aug 18;9(2):101355. doi: 10.1016/j.adro.2023.101355. eCollection 2024 Feb. Adv Radiat Oncol. 2023. PMID: 38405315 Free PMC article. - Advances and Challenges in Conducting Clinical Trials With Proton Beam Therapy.
Choi JI, Simone CB 2nd, Lozano A, Frank SJ. Choi JI, et al. Semin Radiat Oncol. 2023 Oct;33(4):407-415. doi: 10.1016/j.semradonc.2023.06.006. Semin Radiat Oncol. 2023. PMID: 37684070 Free PMC article. Review. - Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer.
Taugner J, Eze C, Käsmann L, Roengvoraphoj O, Gennen K, Karin M, Petrukhnov O, Tufman A, Belka C, Manapov F. Taugner J, et al. Radiat Oncol. 2020 Jun 9;15(1):148. doi: 10.1186/s13014-020-01590-8. Radiat Oncol. 2020. PMID: 32517716 Free PMC article. - Proton reirradiation for recurrent or new primary breast cancer in the setting of prior breast irradiation.
Choi JI, Khan AJ, Powell SN, McCormick B, Lozano AJ, Del Rosario G, Mamary J, Liu H, Fox P, Gillespie E, Braunstein LZ, Mah D, Cahlon O. Choi JI, et al. Radiother Oncol. 2021 Dec;165:142-151. doi: 10.1016/j.radonc.2021.10.010. Epub 2021 Oct 22. Radiother Oncol. 2021. PMID: 34688807 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources